Physician profile
Mark T Hoffmann
NPI 1356342034
$52,496.02
in general payments reported to CMS, 2019-2025
30 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $6,347 · 2021: $5,739 · 2022: $11K · 2023: $4,592 · 2024: $1,557 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735 · Travel and Lodging: $1,668 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $726 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.46 |
| Travel and Lodging | $1,667.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $726.00 |
| Education | $204.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $27,480.88 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $17,364.37 | 2019-2025 | |
| Heartflow, INC. | $1,700.65 | 2023-2024 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $913.82 | 2022-2025 | Uptravi, Opsumit |
| Cvrx, INC. | $632.78 | 2021-2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $532.09 | 2020-2025 | |
| Abbott Laboratories | $509.98 | 2022-2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.43 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $285.04 | 2022-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $278.27 | 2019-2025 | |
| Daxor Corporation | $219.78 | 2024 | Bva-100 |
| Abiomed | $197.83 | 2025 | |
| Edwards Lifesciences Corporation | $196.94 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $155.94 | 2024-2025 | Onpattro, Amvuttra |
| Daiichi Sankyo INC. | $135.34 | 2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $131.78 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $124.89 | 2024 | Inpefa |
| Pfizer INC. | $123.80 | 2022-2023 | |
| Medtronic, INC. | $119.08 | 2022 | |
| Astellas Pharma US INC | $115.00 | 2022 | |
| Inari Medical, INC. | $112.94 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bridgebio Pharma, INC. | $107.80 | 2025 | Attruby |
| Medtronic Vascular, INC. | $101.71 | 2019 | |
| Amgen INC. | $100.45 | 2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2023 | Lifevest |
| Boston Scientific Corporation | $88.87 | 2022 | |
| Merck Sharp & Dohme LLC | $80.72 | 2024-2025 | Winrevair, Verquvo |
| Inspire Medical Systems, INC. | $62.93 | 2024 | Inspire |
| Livanova USA, INC. | $25.28 | 2023 | Lifesparc |
| Kiniksa Pharmaceuticals International, Plc | $19.63 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.